HAVCR2
Hepatitis A virus cellular receptor 2
As of the edition of 20 October 2026, HAVCR2 (hepatitis A virus cellular receptor 2, UniProt Q8TDQ0) has 8 drugs tested at it and 8 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q8TDQ0
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 11
- Disease areas
- Cancer; Blood and lymph; Digestive system; Skin and connective tissue; Lungs and airways; Pregnancy and women's health; Urinary and reproductive; Immune system
- Registered trials of its drugs
- 47
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Stopped | 5 |
| Status not established | 1 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sabatolimab | Active | Phase 3 | none listed |
| Cobolimab | Active | Phase 3 | none listed |
| Verzistobart | Stopped | Phase 2 | none listed |
| TQB2618 | Stopped | Phase 2 | none listed |
| BC3402 | Stopped | Phase 2 | none listed |
| Lomvastomig | Status not established | Phase 2 | none listed |
| SHR-1702 | Stopped | Phase 1 | none listed |
| BMS-986258 | Stopped | Phase 2 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Engaged | 2 |
| Undetermined | 2 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Incyte | Route A |
| Bristol Myers Squibb | Route A |
| Chia Tai Tianqing Pharmaceutical | Route A |
The other 5 companies at HAVCR2
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at HAVCR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.